Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 03, 2015 5:40 PM ET

Life Sciences Tools and Services

Company Overview of NuGEN Technologies, Inc.

Company Overview

NuGEN Technologies, Inc. provides solutions that make biological samples accessible for genomic analysis enabling scientists, researchers, and clinicians to prepare genomic samples. It offers DNA and RNA sample preparation technologies for biomarker discovery, research, diagnostic, expression profiling, and clinical research applications to life scientists; and automation solutions to streamline sample preparation technologies for sequencing, microarray analysis, and qPCR applications. The company provides its products for DNA and RNA analysis applications. It serves customers through a network of distributors in the United States and internationally. The company was founded in 2000 and is b...

201 Industrial Road

Suite 310

San Carlos, CA 94070

United States

Founded in 2000





Key Executives for NuGEN Technologies, Inc.

Chief Executive Officer and Director
Age: 48
Chief Financial Officer
Vice President of Research and Development
Vice President of Worldwide Sales
Vice President of Marketing
Compensation as of Fiscal Year 2015.

NuGEN Technologies, Inc. Key Developments

PreAnalytiX GmbH, NuGEN Technologies and RUCDR Infinite Biologics Partner to Develop Clinically Validated RNA-Seq Workflow for Whole Blood Samples

PreAnalytiX GmbH, NuGEN Technologies, Inc. and RUCDR Infinite Biologics (RUCDR), announced a joint project to validate an end-to-end workflow for the reproducible collection and processing of whole blood for RNA sequencing (RNA-Seq) in clinical studies. The multi-site validation study involves three independent laboratories processing samples collected, stored and transported in the PAXgene Blood RNA System from PreAnalytiX to prepare strand-specific RNA-Seq libraries using NuGEN's Ovation Human Blood RNA-Seq System prior to NGS sequence analysis. RUCDR will oversee all sample collection, processing and data analysis for the purpose of validating the PreAnalytiX and NuGEN offerings in a combined workflow. Whole blood samples are used for a myriad of clinical genomics applications, due in part to the ease of collection as compared to other clinical sample types. However, there are challenges associated with preparation of human whole blood samples for analysis by RNA-Seq.

NuGEN Technologies, Inc. Launches Target Enrichment Technology

NuGEN Technologies, Inc. has launched a novel technology to better enable targeted sequencing studies with genomic DNA or RNA. This launch follows a early access period where the technology has been evaluated in leading genomics labs. NuGEN's proprietary method provides sensitive variant detection, including SNPs, indels, translocations, gene fusions and alternative splicing events with more uniform coverage and lower drop-out rates than currently available bait-capture methods. The method features a rapid and convenient workflow that can be used with genomic material from both fresh and formalin-fixed paraffin-embedded tissues, saving time and expanding sample sources available to the user. The Ovation Custom Target Enrichment System employs NuGEN's Single Primer Enrichment Technology (SPET), and is a complete library and enrichment solution for generation of enriched, multiplexed libraries from low-input amounts of genomic DNA or from cDNA. SPET technology is uniquely designed to provide independent coverage of target regions from both DNA strands, resulting in generation of high quality sequencing data. The rapid, low cost and extremely flexible custom design process has a three week delivery time, and is suitable for use in a range of applications including enrichment for exonic regions, splice variant and gene fusion analysis, long contiguous regions such as mitochondrial DNA and amplified genomic material from single cells. In addition to custom target enrichment offerings, NuGEN is introducing two standard oncological panels for DNA and RNA, respectively. The Ovation Cancer Panel Target Enrichment System enriches over 300 genes associated with cancer and the Ovation Gene Fusion Target Enrichment System is the first truly comprehensive fusion panel of over 400 cancer genes involved in gene fusions. Both systems are available as 8-reaction test kits or 32 and 96 reaction kits.

NuGEN's Novel Technology for RNA-Seq Extends to a Broad Range of Transcript Species

NuGEN Technologies, Inc. has developed a novel solution that enables more informative data to be generated from RNA-Seq studies performed with challenging samples, including model organisms. Human and non-human samples often have uninformative transcript species present in high abundance that can compromise data quality and cost-effectiveness of sequencing. NuGEN's proprietary technology provides targeted depletion of a broad range of uninformative transcripts, a solution not addressed by standard library preparation methods for RNA-Seq. NuGEN's novel method, Insert Dependent Adaptor Cleavage (InDA-C), employs primers during library creation to target specific transcripts for depletion in the final library and is the core technology employed in the Ovation Universal RNA-Seq Library System. Importantly, the method does not perturb the original total RNA input to the workflow. NuGEN provides a no-cost design service to assist researchers in choosing InDA-C primers, and primers can be designed for use with virtually any organism. The result is a significant reduction in sequencing reads derived from unwanted transcripts, including ribosomal RNA, globin and protein-coding RNAs, such as housekeeping genes. Unlike methods that use hybridization-mediated pull-down strategies to deplete unwanted RNA species, the InDA-C method avoids off-target mRNA cross-hybridization events that can potentially introduce bias.

Similar Private Companies By Industry

Company Name Region
INB: Hauser Pharmaceutical Services, Inc. United States
ChemDiv, Inc. United States
AIBioTech Inc. United States
Pinnacle Merger Subordinated Inc United States
SeqWright, Inc. United States

Recent Private Companies Transactions

Private Placement
September 12, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NuGEN Technologies, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at